Dr. Reddy’s Laboratories received Voluntary Licence from Gilead to make the latest generation HIV drug, lenacapavir, accessible to patients in 120 countries
Proud to announce that we have received a royalty-free non-exclusive voluntary licence from Gilead to make the latest generation HIV drug lenacapavir accessible to patients in 120 countries! This marks an important milestone for us in patient access and affordability for pre and post exposure treatment of HIV. This collaboration with Gilead will help us make this latest treatment option available to patients in 120 primarily low- and lower- middle income countries, including India. Many of these countries have a very high disease burden of HIV, making this is an important attempt in our journey to serve over 1.5 billion patients by 2030.
